S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Applied Optoelectronics earnings dumper, pain now for gain later?
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Applied Optoelectronics earnings dumper, pain now for gain later?
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Applied Optoelectronics earnings dumper, pain now for gain later?
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Applied Optoelectronics earnings dumper, pain now for gain later?
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
NASDAQ:ILMN

Illumina (ILMN) Stock Price, News & Analysis

$140.98
+1.22 (+0.87%)
(As of 02/28/2024 ET)
Today's Range
$138.14
$143.17
50-Day Range
$130.34
$147.20
52-Week Range
$89.00
$238.55
Volume
1.18 million shs
Average Volume
1.89 million shs
Market Capitalization
$22.40 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$166.95

Illumina MarketRank™ Stock Analysis

Analyst Rating
Hold
2.32 Rating Score
Upside/​Downside
18.4% Upside
$166.95 Price Target
Short Interest
Healthy
3.01% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
1.04mentions of Illumina in the last 14 days
Based on 22 Articles This Week
Insider Trading
Acquiring Shares
$991,676 Bought Last Quarter
Proj. Earnings Growth
143.00%
From $1.00 to $2.43 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.79 out of 5 stars

Medical Sector

45th out of 958 stocks

Analytical Instruments Industry

2nd out of 29 stocks


ILMN stock logo

About Illumina Stock (NASDAQ:ILMN)

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. Further, it provides whole-genome sequencing, genotyping, NIPT, and product support services; and Galleri, a multi-cancer early detection test. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Further, it markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

ILMN Stock Price History

ILMN Stock News Headlines

Reasons for the Decline of Illumina (ILMN)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Do You Believe in the Growth Prospects of Illumina (ILMN)?
Illumina Inc CEO Jacob Thaysen Acquires 7,330 Shares
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
ILMN Mar 2024 120.000 put
ILMN Mar 2024 140.000 put
ILMN Mar 2024 131.000 call
ILMN Mar 2024 123.000 put
ILMN Mar 2024 120.000 call
ILMN Feb 2024 118.000 call
ILMN Feb 2024 145.000 call
ILMN Feb 2024 138.000 put
ILMN Feb 2024 117.000 put
Critical Insights From Illumina Analyst Ratings: What You Need To Know
ILMN Feb 2024 143.000 call
ILMN Feb 2024 155.000 put
See More Headlines
Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/08/2024
Today
2/29/2024
Next Earnings (Estimated)
4/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:ILMN
CUSIP
45232710
Employees
9,300
Year Founded
1998

Price Target and Rating

Average Stock Price Target
$166.95
High Stock Price Target
$258.00
Low Stock Price Target
$80.00
Potential Upside/Downside
+18.4%
Consensus Rating
Hold
Rating Score (0-4)
2.32
Research Coverage
19 Analysts

Profitability

Net Income
$-1,161,000,000.00
Pretax Margin
-24.80%

Debt

Sales & Book Value

Annual Sales
$4.50 billion
Cash Flow
$3.69 per share
Book Value
$36.15 per share

Miscellaneous

Free Float
158,693,000
Market Cap
$22.40 billion
Optionable
Optionable
Beta
1.22

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Joydeep Goswami M.B.A. (Age 53)
    Ph.D., CFO, Chief Strategy & Corporate Development Officer
    Comp: $787.3k
  • Mr. Jacob Thaysen Ph.D. (Age 49)
    CEO & Director
  • Stephanie Campos
    President
  • Mr. Kevin Carl Pegels (Age 57)
    Chief of Global Operations
  • Mr. Scott Ericksen (Age 52)
    VP & Chief Accounting Officer
  • Dr. Steven Barnard Ph.D.
    Chief Technology Officer
  • Ms. Carissa L. Rollins (Age 54)
    Chief Information Officer
  • Ms. Sallilyn Schwartz
    Vice President of Investor Relations
  • Mr. Charles E. Dadswell Esq. (Age 65)
    Senior VP & General Counsel
    Comp: $1.06M
  • Ms. Kathryne Gambrell Reeves (Age 55)
    Chief Marketing Officer

Should I Buy Illumina Stock? ILMN Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Illumina was last updated on Tuesday, February 27, 2024 at 2:51 PM.

Pros

Here are some ways that investors could benefit from investing in Illumina, Inc.:

  • Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function.
  • Strong presence in key markets such as North America, Europe, Asia-Pacific region, Latin America, the Middle East, and Africa.

Cons

Investors should be bearish about investing in Illumina, Inc. for these reasons:

  • Current stock price may not be favorable for short-term gains.














ILMN Stock Analysis - Frequently Asked Questions

Should I buy or sell Illumina stock right now?

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last twelve months. There are currently 2 sell ratings, 9 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View ILMN analyst ratings
or view top-rated stocks.

What is Illumina's stock price target for 2024?

19 brokerages have issued 12-month price targets for Illumina's shares. Their ILMN share price targets range from $80.00 to $258.00. On average, they predict the company's stock price to reach $166.95 in the next twelve months. This suggests a possible upside of 18.4% from the stock's current price.
View analysts price targets for ILMN
or view top-rated stocks among Wall Street analysts.

How have ILMN shares performed in 2024?

Illumina's stock was trading at $139.24 at the start of the year. Since then, ILMN shares have increased by 1.2% and is now trading at $140.98.
View the best growth stocks for 2024 here
.

When is Illumina's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 23rd 2024.
View our ILMN earnings forecast
.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) announced its earnings results on Thursday, February, 8th. The life sciences company reported $0.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.01 by $0.13. The life sciences company earned $1.12 billion during the quarter, compared to analyst estimates of $1.09 billion. Illumina had a positive trailing twelve-month return on equity of 2.20% and a negative net margin of 25.78%. Illumina's revenue was up 3.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.14 EPS.
Read the conference call transcript
.

What guidance has Illumina issued on next quarter's earnings?

Illumina issued an update on its fourth quarter 2023 earnings guidance on Tuesday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), Salesforce (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

Who are Illumina's major shareholders?

Illumina's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.45%), Edgewood Management LLC (4.33%), Baillie Gifford & Co. (3.32%), GUARDCAP ASSET MANAGEMENT Ltd (1.29%), Capital World Investors (1.23%) and Norges Bank (1.20%). Insiders that own company stock include Aimee L Hoyt, Alexander Aravanis, Charles Dadswell, Jacob Thaysen, Jay T Flatley, Phillip G Febbo, Susan H Tousi and Susan H Tousi.
View institutional ownership trends
.

How do I buy shares of Illumina?

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Illumina have any subsidiaries?
The following companies are subsidiares of Illumina: Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueBee Belgium BVBA, BlueBee Holding BV, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Emedgene Inc., Emedgene Technologies Ltd, Enancio, Enancio SAS, Epicentre Biotechnologies, GRAIL LLC, GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada ULC, Illumina Denmark ApS, Illumina Finland Oy, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus LLC, Illumina Shanghai (Trading) Co Ltd Beijing Branch, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Software Inc., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., Liquid Logic, Moleculo, NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV.
Read More
This page (NASDAQ:ILMN) was last updated on 2/29/2024 by MarketBeat.com Staff